Sat, Nov 29, 2014, 12:09 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Athersys, Inc. Message Board

  • axiomspoon axiomspoon Oct 1, 2013 9:18 PM Flag

    Real Answers from the CEO of Athersys:

    Athersys CEO Gil Van Bokkelen was asked this question at an interview:

    Interviewer: You have a unique cell therapy program that reads out potential stock moving data in 2013 and 2014, and you have multiple, meaningful potential partnerships besides Pfizer on the horizon. What else should a buyer need to know about your company?

    Gil: Frankly, I think that should be sufficient to get people excited; I think it's going to be pretty exciting for us and for the people that own our stock.
    -----------------------------------------------------------------------------------------------------------------------------------------------
    Now in regards to the IBD trial with Pfizer:

    Interviewer: Why are you so confident of a positive result?

    Gil: We've done a lot of pre-clinical work, not only models of inflammatory bowel disease but also in immunological models and inflammatory models generally, and what we see over and over again is that these cells, MultiStem, are very powerful immunomodulators. They can reduce inflammatory damage, and they can restore a durable balance to immune system function, which frankly gets to the root cause of the process that's causing the damage in patients that have inflammatory bowel disease.

    We, and Pfizer, believe that the current trial is an appropriate way to initially evaluate the clinical relevance of MultiStem in a chronic inflammatory immune condition, and if we're successful there, frankly, it opens up a whole other host of possibilities in other inflammatory and immune conditions that will be based on years of pre-clinical work we've done in other indications.

    In our minds, this is very important because it could provide the first evidence in an inflammatory immune condition outside of the work we've already done in preventing graft versus host disease. From a phase II, robustly designed, double blind, placebo-controlled trial, they could actually pave the way for a lot of other opportunities beyond.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ATHX
1.43-0.01(-0.69%)Nov 28 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.